Division of Hematology and Oncology, Department of Medicine
Fluids and Secretions | Hematology | Infectious Disease | Medical Microbiology | Therapeutics | Virus Diseases
As of May 19, 2020, there are in total 4,986,200 laboratory-confirmed Coronavirus disease-2019 (COVID-19) cases. 2% (45,425) out of 2,657,390 active COVID-19 cases are critically ill and might be requiring intensive care support. Unfortunately, even after six months since its first detection, we still do not have any definitive treatment options for COVID-19 pneumonia. Recently, the use of human convalescent plasma is being considered as a potential option for the treatment of COVID-19.
COVID-19, coronavirus, convalescent plasma therapy
Rights and Permissions
© 2020. This is a PDF file of an accepted manuscript that has been accepted for publication and posted with a 12-month embargo as allowed by the publisher’s author rights policy at https://authorservices.wiley.com/author-resources/Journal-Authors/licensing/self-archiving.html. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
DOI of Published Version
Sahu KK, Jindal V, Siddiqui AD, Cerny J, Gerber JM. Convalescent Plasma Therapy: A Passive Therapy for An Aggressive COVID-19. J Med Virol. 2020 May 21. doi: 10.1002/jmv.26047. Epub ahead of print. PMID: 32437024. Link to article on publisher's site
Journal of medical virology
Sahu KK, Jindal V, Siddiqui AD, Cerny J, Gerber JM. (2020). Convalescent Plasma Therapy: A Passive Therapy for An Aggressive COVID-19. COVID-19 Publications by UMMS Authors. https://doi.org/10.1002/jmv.26047. Retrieved from https://escholarship.umassmed.edu/covid19/37